Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Izokibep

Alternative Names: izokibep, aby-035, aby035, aby 035, afo2, aby-035/afo2, IMG020, IMG-020
Latest Update: 2025-04-04
Latest Update Note: Clinical Trial Update

Product Description

Izokibep is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of existing monoclonal antibodies.

Mechanisms of Action: IL17A Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ACELYRIN
Company Location:
Company CEO:
Additional Commercial Interests: Affibody

Clinical Description

Map of Global Clinical Trials for Izokibep

Countries in Clinic: Austria, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, United States, Unknown Location

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Arthritis, Psoriatic|Hidradenitis Suppurativa

Phase 2: Spondylitis, Ankylosing|Uveitis, Intermediate|Uveitis, Posterior

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2031230501

P3

Not yet recruiting

Hidradenitis Suppurativa

2025-12-31

2021-006498-49

P2

Active, not recruiting

Uveitis, Posterior|Uveitis, Intermediate

2025-06-05

21103

P2

Completed

Uveitis, Intermediate|Uveitis, Posterior

2025-01-07

22104

P3

Completed

Arthritis, Psoriatic

2024-10-03

Recent News Events

Date

Type

Title

12/10/2024

News Article

 ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

08/06/2024

News Article

 ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024

06/05/2024

News Article

 ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

05/29/2024

News Article

 ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

03/19/2024

PubMed

 Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.

03/01/2024

PubMed

 An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa.

10/11/2023

PubMed

 IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions